C-cell hyperplasia, pheochromocytoma and sympathoadrenal malformation in a mouse model of multiple endocrine neoplasia type 2B

EMBO Journal

Volumn 19, Issue 4, 2000, Pages 612-622

  Smith Hicks, Constance L ^a   Sizer, Kurt C ^a   Powers, James F ^b   Tischler, Arthur S ^b   Costantini, Frank ^a  

^a Columbia University ^*  (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

C cells; MEN2B; Pheochromocytoma; RET receptor tyrosine kinase; Sympathetic ganglia

Indexed keywords

PROTEIN TYROSINE KINASE;

ADRENAL MEDULLA; AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL HYPERPLASIA; CHROMAFFIN CELL; ENZYME SPECIFICITY; FEMALE; GANGLIONEUROMA; GASTROINTESTINAL TUMOR; GENE MUTATION; HOMOZYGOTE; MALE; MALE INFERTILITY; MOUSE; NEUROFIBROMATOSIS; NONHUMAN; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; PROTO ONCOGENE; SIGNAL TRANSDUCTION; THYROID CELL;

ANIMALIA;

EID: 0034651526     PISSN: 02614189     EISSN: None     Source Type: Journal    
DOI: 10.1093/emboj/19.4.612     Document Type: Article

References (55)

1. Airaksinen, M.S., Titievsky, A. and Saarma, M. (1999) GDNF family neurotrophic factor signaling: four masters, one servant? Mol. Cell. Neurosci., 13, 313-325.
2. Asai, N., Iwashita, T., Matsuyama, M. and Takahashi, M. (1995) Mechanism of activation of the ret proto-oncogene by multiple endocrine neoplasia 2A mutations. Mol. Cell. Biol., 15, 1613-1619.
3. Bocciardi, R., Mograbi, B., Pasini, B., Borrello, M.G., Pierotti, M.A., Bourget, I., Fischer, S., Romeo, G. and Rossi, B. (1997) The multiple endocrine neoplasia type 2B point mutation switches the specificity of the Ret tyrosine kinase towards cellular substrates that are susceptible to interact with Crk and Nck. Oncogene, 15, 2257-2265.
4. Borrello, M.G. et al. (1995) RET activation by germline MEN2A and MEN2B mutations. Oncogene, 11, 2419-2427.
5. Carlson, K.M., Dou, S., Chi, D., Scavarda, N., Toshima, K., Jackson, C.E., Wells, S.A., Goodfellow, P.J. and Donis-Keller, H. (1994) Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B. Proc. Natl Acad. Sci. USA, 91, 1579-1583.
6. Carney, J.A., Sizemore, G.W. and Sheps, S.G. (1976) Adrenal medullary disease in multiple endocrine neoplasia, type 2: pheochromocytoma and its precursors. Am. J. Clin. Pathol., 66, 279-90.
7. Carney, J.A., Sizemore, G.W. and Hayles, A.B. (1978) Multiple endocrine neoplasia, type 2b. Pathabiol. Annu., 8, 105-153.
8. Coupland, R.E. (1960) The post-natal distribution of the abdominal chromaffin tissue in the guinea pig, mouse and white rat. J. Anal., 94, 244-256.
9. Dale, E.G. and Ow, D.W. (1991) Gene transfer with subsequent removal of the selection gene from the host genome. Proc. Natl Acad. Sci. USA, 88, 10558-10562.
10. DeLellis, R.A., Wolfe, H.J., Gagel, R.F., Feldman, Z.T., Miller, H.H., Gang, D.L. and Reichlin, S. (1976) Adrenal medullary hyperplasia. A morphotnetric analysis in patients with familial medullary thyroid carcinoma. Am. J. Pathol., 83, 177-196.
11. Donis-Keller, H. et al. (1993) Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum. Mol. Genet., 2, 851-856.
12. Doupe, A.J., Landis, S.C. and Patterson, P.H. (1985) Environmental influences in the development of neural crest derivatives: glucocorticoids, growth factors, and chromaffin cell plasticity. J. Neurosci., 5, 2119-2142.
13. Durbec, P.L., Larsson-Blomberg, L.B., Schuchardt, A., Costantini, F. and Pachnis, V. (1996) Common origin and developmental dependence on c-ret of subsets of enteric and sympathetic neuroblasts. Development, 122, 349-358.
14. Edery, P. et al. (1994) Mutations of the RET proto-oncogene in Hirschsprung's disease. Nature, 367, 378-380.
15. Edery, P., Eng, C., Munnich, A. and Lyonnet, S. (1997) RET in human development and oncogenesis. BioEssays, 19, 389-395.
16. Eng, C. et al. (1994) Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours. Hum. Mol. Genet., 3, 237-241.
17. Golden, J.P., DeMaro, J.A., Osborne, P.A., Milbrandt, J. and Johnson, E.M., Jr (1999) Expression of neurturin, GDNF, and GDNF family-receptor mRNA in the developing and mature mouse. Exp. Neurol., 158, 504-528.
18. Hofstra, R.M. et al. (1994) A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature, 367, 375-376.
19. Landsvater, R.M., de Wit, M.J., Zewald, R.A., Hofstra, R.M., Buys, C.H., Ploos van Amstel, H.K., Hoppener, J.W. and Lips, C.J. (1996) Somatic mutations of the RET proto-oncogene are not required tor tumor development in multiple endocrine neoplasia type 2 (MEN 2) gene carriers. Cancer Res., 56, 4853-4855.
20. Lewandoski, M. and Martin, G.R. (1997) Cre-mediated chromosome loss in mice. Nature Genet., 17, 223-225.
21. Liu, X., Vega, Q.C., Decker, R.A., Pandey, A., Worby, C.A. and Dixon, J.E. (1996) Oncogenic RET receptors display different autophosphorylation sites and substrate binding specificities. J. Biol. Chem., 271, 5309-5312.
22. Lloyd, R.V., Sisson, J.C., Shapiro, B. and Verhofstad, A.A. (1986) Immunohistochemical localization of epinephrine, norepinephrine, catecholamine-synthesizing enzymes, and chromogranin in neuroendocrine cells and tumors. Am. J. Pathol., 125, 45-54.
23. Longeart, L.E. (1996) Adrenal medullary tumors, mouse. In Jones, T.C., Capen, CC. and Mohr, U. (eds), Monographs on Pathology of Laboratory Animals. Endocrine System, Springer-Verlag, Berlin, Germany, pp. 421-427.
24. Matias-Guiu, X., Peiro, G., Esquius, J., Oliva, E., Cabezas, R., Colomer, A. and Prat, J. (1995) Proliterative activity in C-cell hyperplasia and medullary thyroid carcinoma. Evaluation by PCNA immunohistochemistry and AgNORs staining. Pathol Res. Pract., 191, 42-47.
25. McGregor, L.M., McCune, B.K., Graff, J.R., McDowell, P.R., Romans, K.E., Yancopoulos, G.D., Ball, D.W., Baylin, S.B. and Nelkin, B.D. (1999) Roles of trk family neurotrophin receptors in medullary thyroid carcinoma development and progression. Proc. Natl Acad. Sci. USA, 96, 4540-4545.
26. Michiels, F.M., Chappuis, S., Caillou, B., Pasini, A., Talbot, M., Monier, R., Lenoir, G.M., Feunteun, J. and Billaud, M. (1997) Development of medullary thyroid carcinoma in transgenic mice expressing the RET protooncogene altered by a multiple endocrine neoplasia type 2A mutation. Proc. Natl Acad Sci. USA, 94, 3330-3335.
27. Moens, C.B., Auerbach, A.B., Conlon, R.A., Joyner, A.L. and Rossant, J. (1992) A targeted mutation reveals a role for N-myc in branching morphogenesis in the embryonic mouse lung. Genes Dev., 6, 691-704.
28. Mulligan, L.M. et al. (1993) Germ-line mutations of the RET protooncogene in multiple endocrine neoplasia type 2A. Nature, 363, 458-460.
29. Murakami, H., Iwashita, T., Asai, N., Shimono, Y., Iwata, Y., Kawai, K. and Takahashi, M. (1999) Enhanced phosphatidylinositol 3-kinase activity and high phosphorylation state of its downstream signalling molecules mediated by ret with the MEN 2B mutation. Biochem. Biophys. Res. Commun., 262, 68-75.
30. Pachnis, V. Mankoo, B.S. and Costantini, F. (1993) Expression of the c-ret proto-oncogene during mouse embryogenesis. Development, 119, 1005-1017.
31. Pandit, S.D., Donis-Keller, H., Iwamoto, T., Tomich, J.M. and Pike, L.J. (1996) The multiple endocrine neoplasia type 2B point mutation alters long-term regulation and enhances the transforming capacity of the epidermal growth factor receptor. J. Biol. Chem., 271, 5850-5858.
32. Pasini, B., Ceccherini, I. and Romeo, G. (1996) RET mutations in human disease. Trends Genet., 12, 138-144.
33. Pegoraro, R.J., Hacking, D.J., Buck, R.H., Rom, L., Lanning, P.A. and Berger, G.M. (1998) Molecular diagnosis of multiple endocrine neoplasia type 2A. S. Afr. Med. J., 88, 39-42.
34. Ponder, B.A. and Smith, D. (1996) The MEN II syndromes and the role of the ret proto-oncogene. Adv. Cancer Res., 70, 179-222.
35. Romeo, G. et al. (1994) Point mutations affecting the tyrosine kinase domain of the RET proto-oncogene in Hirschsprung's disease. Nature, 367, 377-378.
36. Rosenthal, A. (1999) The GDNF protein family: gene ablation studies reveal what they really do and how. Neuron, 22, 201-203.
37. Rossel, M. et al. (1997) Distinct biological properties of two RET isoforms activated by MEN 2A and MEN 2B mutations. Oncogene, 14, 265-275.
38. Santoro, M. et al. (1995) Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science, 267, 381-383.
39. Sauer, B. (1993) Manipulation of transgenes by site-specific recombination: use of Cre recombinase. Methods Enzymol., 225, 890-900.
40. Schuchardt, A., D'Agati, V., Larsson-Blomberg, L., Costantini, F. and Pachnis, V. (1994) Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor Ret. Nature, 367, 380-383.
41. Schuchardt, A., D'Agati, V., Pachnis, V. and Costantini, F. (1996) Renal agenesis and hypodysplasia in ret-k-mutant mice result from defects in ureteric bud development. Development, 122, 1919-1929.
42. Shi, S.R., Cote, C, Kalra, K.L., Taylor, C.R. and Tandon, A.K. (1992) A technique for retrieving antigens in formalin-fixed, routinely acid-decalcified, celloidin-embedded human temporal bone sections for immunohistochemistry. J. Histochem. Cytochem., 40, 787-792.
43. Smith, D.P., Houghton, C. and Ponder, B.A. (1997) Germline mutation of RET codon 883 in two cases of de novo MEN 2B. Oncogene, 15, 1213-1217.
44. Songyang, Z. et al. (1995) Catalytic specificity of protein-tyrosine kinases is critical for selective signalling. Nature, 373, 536-539.
45. Sweetser, D.A., Kapur, R.P., Froelick, G.J., Kafer, K.E. and Palmiter, R.D. (1997) Oncogenesis and altered differentiation induced by activated Ras in neuroblasts of transgenic mice. Oncogene, 15, 2783-2794.
46. Sweetser, D.A., Froelick, G.J., Matsumoto, A.M, Kafer, K.E., Marck, B., Palmiter, R.D. and Kapur, R.P. (1999) Ganglioneuromas and renal anomalies are induced by activated RET(MEN2B) in transgenic mice. Oncogene, 18, 877-886.
47. Takahashi, M. (1995) Oncogenic activation of the ret protooncogene in thyroid cancer. Crit. Rev. Oncogen., 6, 35-46.
48. Takahashi, M., Buma, Y., Iwamoto, T., Inaguma, Y., Ikeda, H. and Hiai, H. (1988) Cloning and expression of the ret proto-oncogene encoding a tyrosine kinase with two potential transmembrane domains. Oncogene, 3, 571-578.
49. Takahashi, M., Buma, Y. and Hiai, H. (1989) Isolation of ret proto-oncogene cDNA with an amino-terminal signal sequence. Oncogene, 4, 805-806.
50. Tischler, A.S. (1999) Cell proliferation and neoplastic progression in the adrenal medulla: insights and questions from immunohistochemical studies. Acta Histochem. Cytochem., 32, 121-126.
51. Tischler, A.S. and Semple, J. (1996) Adrenal medullary nodules in Beckwith-Wiedemann syndrome resemble extra-adrenal paraganglia. Endocr. Pathol., 7, 265-272.
52. Tischler, A.S., Shih, T.S., Williams, B.O. and Jacks, T. (1995) Characterization of pheochromocytomas in a mouse strain with a targeted disruptive mutation of the neurofibromatosis gene Nf1. Endocr. Pathol., 6, 323-335.
53. Tischler, A.S., Sheldon, W. and Gray, R. (1996) Immunohistochemical and morphological characterization of spontaneously occurring pheochromocytomas in the aging mouse. Vet. Pathol., 33, 512-520.
54. Tsuzuki, T., Takahashi, M., Asai, N., Iwashita, T., Matsuyama, M. and Asai, J. (1995) Spatial and temporal expression of the ret proto-oncogene product in embryonic, infant and adult rat tissues. Oncogene, 10, 191-198.
55. Wolfe, H.J., Melvin, K.E., Cervi-Skinner, S.J., Saadi, A.A., Juliar, J.F., Jackson, C.E. and Tashjian, A.H., Jr (1973) C-cell hyperplasia preceding medullary thyroid carcinoma. N. Engl. J. Med., 289, 437-441.